Formulation for lipophilic agents
DC CAFCFirst Claim
Patent Images
1. A parenteral formulation, comprising a lipophilic drug which is doxercalciferol, a non-ionic solubilizer which is polysorbate 20 present at a concentration of about 0.05% to about 5% w/w, a lipophilic antioxidant which is butylated hydroxytoluene (BHT) present at a concentration of about 20 to about 2000 ppm, an optional agent which is ethanol present at a concentration of 0 to 30% w/w, and an aqueous vehicle.
4 Assignments
Litigations
0 Petitions
Reexamination
Accused Products
Abstract
The invention relates to pharmaceutical formulations of lipophilic therapeutic agents in which such agents are solubilized in largely aqueous vehicles, and processes for preparing and using the same.
-
Citations
6 Claims
- 1. A parenteral formulation, comprising a lipophilic drug which is doxercalciferol, a non-ionic solubilizer which is polysorbate 20 present at a concentration of about 0.05% to about 5% w/w, a lipophilic antioxidant which is butylated hydroxytoluene (BHT) present at a concentration of about 20 to about 2000 ppm, an optional agent which is ethanol present at a concentration of 0 to 30% w/w, and an aqueous vehicle.
-
6. A parenteral formulation suitable for treatment of secondary hyperparathyroidism comprising 2–
- 10 μ
g/mL of doxercalciferol 0.5%–
2.5% w/w polysorbate 20, 20 ppm BHT and 2.5% w/w ethanol.
- 10 μ
Specification